Viatris Inc (NASDAQ:VTRS) shares traded 0.33% higher at $9.40 on Wall Street last session.
In accordance with the data, 11 analysts cover Viatris Inc (NASDAQ:VTRS). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $9.00, we find $11.00. Given the previous closing price of $9.37, this indicates a potential upside of 17.4 percent. VTRS stock price is now -0.08% away from the 50-day moving average and -5.67% away from the 200-day moving average. The market capitalization of the company currently stands at $11.28B.
It has been rated a hold by 6 analysts and a buy by 2. Brokers who have rated the stock have averaged $11.41 as their price target over the next twelve months.
With the price target reduced from $13 to $9, BofA Securities Downgraded its rating from Neutral to Underperform for Viatris Inc (NASDAQ: VTRS).
In other news, Ni Xiangyang (Sean), President, Greater China sold 14,937 shares of the company’s stock on Nov 24. The stock was sold for $139,942 at an average price of $9.37. Upon completion of the transaction, the President, Greater China now directly owns 64,658 shares in the company, valued at $0.61 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 06, President, Greater China Ni Xiangyang (Sean) sold 3,148 shares of the business’s stock. A total of $34,891 was realized by selling the stock at an average price of $11.08. This leaves the insider owning 46,416 shares of the company worth $0.44 million. Insiders disposed of 647,975 shares of company stock worth roughly $6.09 million over the past 1 year. A total of 1.95% of the company’s stock is owned by insiders.
Viatris Inc (NASDAQ: VTRS) opened at $9.39 on Friday. During the past 12 months, Viatris Inc has had a low of $8.74 and a high of $12.40. As of last week, the company has a debt-to-equity ratio of 0.89, a current ratio of 1.60, and a quick ratio of 1.06. The fifty day moving average price for VTRS is $9.40 and a two-hundred day moving average price translates $9.95 for the stock.
The latest earnings results from Viatris Inc (NASDAQ: VTRS) was released for Sep, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.79, beating analysts’ expectations of $0.74 by 0.05. This compares to $0.29 EPS in the same period last year. The net profit margin was 11.88% and return on equity was 9.15% for VTRS. The company reported revenue of $3.94 billion for the quarter, compared to $4.08 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -3.34 percent. For the current quarter, analysts expect VTRS to generate $3.87B in revenue.
Viatris Inc(VTRS) Company Profile
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
